Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
April 15, 2025
Bristol Myers Squibb announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive